297 filings
6-K
ENLV
Enlivex Therapeutics Ltd
22 Apr 24
Report of Foreign Private Issuer
8:02am
6-K
ENLV
Enlivex Therapeutics Ltd
16 Apr 24
Report of Foreign Private Issuer
8:00am
6-K
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
ENLV
Enlivex Therapeutics Ltd
29 Mar 24
Report of Foreign Private Issuer
4:30pm
6-K
ENLV
Enlivex Therapeutics Ltd
7 Feb 24
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
8:02am
6-K
3cmjn0o
22 Jan 24
Report of Foreign Private Issuer
8:00am
6-K
xai3ckacsze 2w
17 Jan 24
Report of Foreign Private Issuer
8:02am
6-K
x49joh5of
20 Dec 23
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
8:01am
6-K
ksxsxurkm
9 Nov 23
Condensed Consolidated Financial Statements
4:30pm
6-K
1stqt0knlh 3h8k0hr
7 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
jmbqb
2 Nov 23
Report of Foreign Private Issuer
4:30pm
6-K
gmv 29uy1viulx6ce
26 Oct 23
Report of Foreign Private Issuer
4:30pm
6-K
bqqgkn euuzc
18 Sep 23
Report of Foreign Private Issuer
8:00am
6-K
oy33lroox7amo
13 Sep 23
Notice of Annual General Meeting of Shareholders
4:42pm
6-K
3bekf4 3ihy6e4o2iy85
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
rumqcibppb raf9
1 Sep 23
Condensed Consolidated Financial Statements
4:30pm
6-K
16ds5r2iu l681ab3
2 Aug 23
Report of Foreign Private Issuer
8:05am
6-K
o0rx 1xl3jdo4imtrw50
31 Jul 23
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
8:05am
6-K
xy7pfw
26 Jun 23
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update
8:03am
6-K
ryoge1dtocc095es 3l
16 Jun 23
Condensed Consolidated Financial Statements
4:30pm